Daptomycin compositions
A stable daptomycin composition with L-arginine and pH adjusting agents addresses long reconstitution times and chemical instability, providing rapid reconstitution and reduced impurities for efficient parenteral use.
WO2026111848A1 Publication Date: 2026-05-28MAIA PHARMACEUTICALS INC
13 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/052069
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-15
- Filing Date
- 2025-10-22
- Publication Date
- 2026-05-28
AI Technical Summary
Technical Problem
Existing daptomycin compositions require long reconstitution times (15-45 minutes) and suffer from chemical instability, leading to potential adverse effects and impurity issues during parenteral administration.
Method used
A stable solid pharmaceutical composition comprising daptomycin, a basic amino acid (e.g., L-arginine or its salt) and pH adjusting agents, with a molar ratio of 1:3.5 to 1:7, which can be reconstituted in less than 15 minutes and exhibits reduced impurity formation under various storage conditions.
Benefits of technology
The composition achieves rapid reconstitution, enhanced chemical stability, and reduced impurity levels, ensuring safer and more efficient parenteral administration with improved shelf life and handling.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure provides daptomycin formulations which have improved chemical stability, faster reconstitution times when reconstituted from the solid state and longer in-use stability. The compositions comprise daptomycin, one basic amino acid or its salt and optionally one or more pH adjusting agents.
Need to check novelty before this filing date? Find Prior Art